News

There is so much happening across Glasgow and the West of Scotland and our news portal will allow us to share it with you.

Landmark drug trial could revolutionise treatment for type 1 diabetes

Finger prick

University of Glasgow researchers are eagerly anticipating the initiation of a pioneering new global trial, described by the funder as “the single most advanced drug-based study to date in type 1 diabetes".

The TTT1 trial – funded by JDRF, the leading global organisation funding type 1 diabetes research, and co-led by State University of New York – will begin in Scotland in early 2020 and aims to help the overwhelming number of individuals with the condition for whom blood glucose (sugar) is still not controlled to target levels, despite improvements in technology including insulin pumps and continuous glucose monitoring.

The TTT-1 trial is led by the University of Glasgow’s global leader in the treatment of type 1 diabetes, Dr John Petrie, Professor of Diabetic Medicine. The trial aims to address a gap in current diabetes treatment, which sees a majority of people on insulin therapy with HbA1c above the recommended target of 7 per cent, indicating high blood glucose over the previous two to three months.

The trial will assess a new combination therapy with insulin, balancing the effects of two drugs called dapagliflozin and semaglutide.

Dapagliflozin (Forxiga), as well as a drug related to semaglutide called liraglutide (Victoza), can improve control in adults with type 1 diabetes. Dapagliflozin has recently been approved for this purpose in the UK and Europe; however, neither drug alone consistently gets most people with type 1 diabetes to the recommended target HbA1c.

Dr Petrie said: “The hope is to use the combination therapy of dapagliflozin and semaglutide to reduce HbA1c to less than 7 per cent in the majority of people with type 1 diabetes; and since these drugs have benefits for the heart and can also induce weight loss, there may be additional advantages of this drug combination, which would be very positive for those with the condition.

“In addition, both dapagliflozin and semaglutide are likely to reduce unpredictable fluctuations in blood glucose levels, thus providing a greater sense of security for people with type 1 diabetes, substantially improving quality of life.”

Rachel Connor, Director of Research Partnerships at JDRF, said: “Type 1 diabetes is a really challenging condition to manage, and the limitations of the tools we have today, both technologies and medicines, mean that many people living with the condition struggle to achieve the glucose management targets recommended by doctors.

“We’re proud to support the TTT1 trial and are hopeful that this will lead to a new way to help people with type 1 reduce HbA1c and so also reduce their risk of developing long term complications.”

 

Links

University of Glasgow


No Comments...


Add a comment

01 00 04 00 Audio Captcha
Add Comment
 

 

What’s happening

This is a living, breathing website with regular updates on news, blogs and events. It’s the place to come back to again and again if you want to know what’s happening in the science and technology world in Glasgow and the West of Scotland.

Subscribe to keep up to date on our latest news, blog posts and events.

News

   

Protein antibiotics offer new hope for fighting common crop diseases

Scientists have tested a new way to protect crops from a widespread and devastating bacterial diseas...

Read more...


Businesses awarded £1.25m in Scottish EDGE round 15

Businesses with high growth potential from across Scotland have benefited to the tune of around £1 ...

Read more...


CAN DO Innovation Challenge Fund opens

Do you have a challenge you can't solve alone? The CAN DO Innovation Challenge Fund is on the hunt f...

Read more...

Blog

   

Game of Drones: A Song of Boats and LiDAR

Drones in the sky, drones in the sea, drones on land. Could drones be doing more for you? At Art of ...

Read more...


Grounds to create global change

To mark International Zero Waste Week Scott Kennedy, co-founder of Revive Eco and member of Industri...

Read more...


Learning to fuel the growth of a more sustainable world

Rachel Clark from the Industrial Biotechnology Innovation Centre (IBioIC) encourages students into s...

Read more...

Events

   

Creative Conversations: Nina Allan

Nina Allan is a writer and critic, active in the field of speculative fiction. Her work has been awa...

Read more...


Culture Club

A monthly gathering of fermentation enthusiasts where you can meet like-minded people and share reci...

Read more...


Matt Dillahunty: Magic, Skepticism & Questions

Matt Dillahunty is well-known as one of the hosts of the popular Atheist Experience phone-in show (w...

Read more...

previous post next post